Other substances

B38

An anti-SARS-CoV-2 monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

B38 is a human anti-SARS-CoV2 monoclonal antibody. It was isolated from a memory B cell from a serum sample of a COVID-19 convalescent patient. It was selected for its affinity for Spike protein RBD. It neutralized SARS-CoV-2 in vitro. The antibody acted synergistically with H4. It reduced viral titres and protected mice from infection-induced weight loss and lung pathology after a challenge (Wu et al., 2020). B38 can be produced in a Nicotiana benthamiana plant expression system (Shanmugaraj et al., 2020).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana Neutralize SARS-CoV-2 in vitro Spike protein In vitro Antibody	in vitro binding assay; Vero E6 cells; SARS-CoV-2 strain SARS-CoV-2/01/human/Jan2020/Thailand	4.40	The antibody experimentally produced using a plant expression system bound SARS-CoV-2 Spike RBD in vitro and neutralised SARS-CoV-2 live virus in Vero E6 cells. It was less potent than <a href=	Nov/27/2020
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Spike protein Biophysical assay Animal model In vitro Antibody Screening	in vitro biophysical assay; crystallization; Vero cells; hACE2 mice; SARS-CoV-2 strain BetaCoV/Shenzhen/SZTH-003/2020	41.85	The antibody neutralized SARS-CoV-2 with an IC50 of 0.177 μg/mL in vitro. It acted synergistically with H4. The antibody reduced viral titres and reduced lung pathology in mice after a challenge.	Jun/12/2020

AI-suggested references

Link	Publication date
Ramsay Hunt syndrome and mRNA SARS-COV-2 vaccination.	Nov/23/2021
An engineered bispecific human monoclonal antibody against SARS-CoV-2.	Feb/28/2022
Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein.	Jul/23/2020
Lysine beta-Hydroxybutyrylation Improves Stability of COVID-19 Antibody.	Dec/08/2021
Interaction Analysis on the SARS-CoV-2 Spike Protein Receptor Binding Domain Using Visualization of the Interfacial Electrostatic Complementarity	Jun/08/2021
Structural insights revealed by crystal structure of B38-CAP, an isoenzyme of carboxypeptidase ACE2, the receptor of SARS-CoV-2	Mar/18/2022
Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations.	Jan/14/2021
Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses	Mar/02/2021
E484K and N501Y SARS-CoV 2 Spike Mutants Increase ACE2 Recognition but Reduce Affinity for Neutralizing Antibody	Jul/28/2020
Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG	Aug/16/2021
Monoclonal antibody as a potential anti-COVID-19	Oct/01/2021
Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19	Jun/30/2020
Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions	Feb/17/2022
Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies	Nov/30/2021
Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.	Aug/17/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04375046	Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2	Not yet recruiting	Phase 1	Jul/01/2021	Oct/01/2021
Alternative id - proposed by Mahmoud kazazzaz Interventions - Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 24 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Time course of body temperature (fever)\|Viral load over time\|P/F ratio over time\|Sequential organ failure assessment score(SOFA score) over time\|Pulmonary Severity Index (PSI)\|Image examination of chest over time\|Proportion of subjects who progressed to critical illness or death\|Time from first dose to conversion to normal or mild pneumonia\|T-lymphocyte counts over time\|C-reactive protein levels over time\|Angiotensin II (Ang II) changes over time\|Angiotensin 1-7 (Ang 1-7) changes over time\|Angiotensin 1-5 (Ang 1-5) changes over time\|Renin changes over time\|Aldosterone changes over time\|Angiotensin-converting enzyme (ACE) changes over time\|Angiotensin-converting enzyme 2 (ACE2) changes over time\|Interleukin 6 (IL-6) changes over time\|Interleukin 8 (IL-8) changes over time\|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time\|Plasminogen activator inhibitor type-1 (PAI-1) changes over time\|Von willebrand factor (vWF) changes over time\|Tumor necrosis factor-α (TNF-α) changes over time\|Soluble receptor for advanced glycation end products (sRAGE) changes over time\|Surfactant protein-D (SP-D) changes over time\|Angiopoietin-2 changes over time\|Frequency of adverse events and severe adverse events
NCT04382950	Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	Not yet recruiting	Phase 1	Jul/01/2021	Oct/01/2021
Alternative id - COV-2019 Treatment This is Interventions - Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 24 Age - 18 Years to 60 Years (Adult) Outcome measures - Time course of body temperature (fever)\|Viral load over time\|P/F ratio over time\|Sequential organ failure assessment score(SOFA score) over time\|Pulmonary Severity Index (PSI)\|Image examination of chest over time\|Proportion of subjects who progressed to critical illness or death\|Time from first dose to conversion to normal or mild pneumonia\|T-lymphocyte counts over time\|C-reactive protein levels over time\|Angiotensin II (Ang II) changes over time\|Angiotensin 1-7 (Ang 1-7) changes over time\|Angiotensin 1-5 (Ang 1-5) changes over time\|Renin changes over time\|Aldosterone changes over time\|Angiotensin-converting enzyme (ACE) changes over time\|Interleukin 6 (IL-6) changes over time\|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time\|Plasminogen activator inhibitor type-1 (PAI-1) changes over time\|Von willebrand factor (vWF) changes over time\|Tumor necrosis factor-α (TNF-α) changes over time\|Soluble receptor for advanced glycation end products (sRAGE) changes over time\|Surfactant protein-D (SP-D) changes over time\|Frequency of adverse events and severe adverse events

Export (.csv)